The use of MALDI-TOF mass spectrometry (MS) in quantitative glycan profiling has not been reported. In this study, we attempted to establish a high-throughput quantitative assay for profiling serum N-glycome, and we applied the new assay to identifying serum N-glycans for diagnosis of liver fibrosis and cirrhosis. Methods: N-Glycans from whole serum proteins in 2 L serum were released by enzymatic digestion, cleaned up by hydrophilic chromatography, and subsequently quantitatively profiled with a linear MALDI-TOF MS system, which was originally designed for quantitative proteomic profiling. Serum N-glycome profiles from 46 patients with chronic hepatitis B infection and with different degrees of liver fibrosis were examined. Results: The intra-and interassay CVs of peak intensities of the standard N-glycans were <8% and <17%, respectively. When the assay was applied to the analysis of serum N-glycome profiles, 17 peaks were found to be potential biomarkers for detection of liver fibrosis/ cirrhosis. Linear regression analysis revealed that 4 peaks of 1341.5, 1829.7, 1933.3, and 2130.3 m/z (all P <0.005) had complementary value in detecting liver fibrosis and included them, but not any serological markers, in the diagnostic model. Leave-one-out crossvalidation showed the diagnostic model could identify significant fibrosis (Ishak score >3) and cirrhosis (Ishak score >5), both at 85% accuracy.
mass spectrometer, a relatively cheaper instrument, has been used for characterization of carbohydrate structure for many years (12, 16 ) . In the past 5 years, MALDI-TOF MS-based instruments, such as SELDI ProteinChip system (17, 18 ) and the ClinProt system (19 ) , have been used for quantitative profiling of the serum proteome.
The feasibility of using MALDI-TOF MS for quantitative profiling of the glycome remained uncertain. In this study, we attempted to establish a high-throughput quantitative assay for profiling the serum N-glycome by using the MALDI-TOF MS function and spectrum analysis programs of the SELDI ProteinChip system. We also used the new assay to search for serum N-glycans, the concentrations of which were altered in patients with liver fibrosis, to serve as an example of the clinical potential of the assay.
Materials and Methods patient materials
Liver biopsies were obtained from consecutive patients with chronic hepatitis B in the Prince of Wales Hospital, Hong Kong, in 2002 and 2003. Patients included those who had been recruited or screened for other therapeutic trials, as well as patients who were suspected of having active liver disease on the basis of laboratory or radiologic investigations. No patients were undergoing treatment at the time of liver biopsy or had compensated liver disease at the time of recruitment. After obtaining informed consent, we collected fasting blood samples by venipuncture before liver biopsy. Serum was stored at Ϫ70°C. Randomly selected serum samples from 46 patients [35 males and 11 females; mean (SD) age, 48.3 (9.2) years] were archived for this study. The same set of samples had been subjected to proteomic profiling in our previous study (18 ) . Age was calculated to the date of biopsy. Use of these clinical samples for biomarker discovery was approved by the university ethics committee. The data of the histological staging (Ishak score reflecting the degrees of liver fibrosis) and hematologic and biochemical tests [complete blood screens, coagulation tests, bilirubin, total protein, albumin, alanine transaminase, alkaline phosphatase (ALP), and ␣-fetoprotein (AFP)] were retrieved from the database of our previous study (18 ) . Ten patients had minimal fibrosis (Ishak score ϭ 1), 9 had mild fibrosis (Ishak score ϭ 2), 10 had moderate fibrosis (Ishak score ϭ 3 or 4), 8 had severe fibrosis and incomplete cirrhosis (Ishak score ϭ 5), and 9 had probable/definite cirrhosis (Ishak score ϭ 6).
design of an assay for quantitative profiling of serum n-glycome N-Glycans from whole serum proteins in 2 L serum were released by enzymatic digestion, cleaned up by hydrophilic chromatography, and then quantitatively profiled with a linear MALDI-TOF MS system, which was originally designed for quantitative proteomic profiling. The mass spectra were analyzed with the existing computer programs designed for quantitative proteomic profiling. Fig. 1 detachment of n-glycans from whole serum proteins We denatured 2 L of serum at 56°C in 20 L of 12.5 mmol/L sodium phosphate buffer (pH 8.3) containing 2.5 mL/L ␤-mercaptoethanol (Sigma-Aldrich) and 1.25 g/L sodium dodecyl sulfate (Sigma-Aldrich) for 1 h and then added 5 L of 100 mL/L Triton X-100 (Sigma-Aldrich) to neutralize the denaturing effect of the sodium dodecyl sulfate. We then added 25 L of 50 mmol/L sodium phosphate buffer (pH 8.3) containing 0.5 U of peptide:Nglycosidase F (PNGase F; EC 3.5.1.52; Sigma-Aldrich). The digestion mixture was incubated at 37°C for 24 h.
microscale purification of serum n-glycome by hydrophilic chromatography A method originally developed for purification of glycopeptides (20 ) was modified in this study to purify Nglycans. We equilibrated 10 mg of preswollen Sepharose 4B gel (GE Healthcare Life Sciences) twice with 0.5 mL of binding solution (butanol:ethanol:7 mmol/L manganese chloride solution ϭ 5:1:1, vol/vol/vol). We diluted 8 L of the enzymatic digest with 200 L of binding solution, mixed this with the gel in a 0.5-mL microcentrifuge tube, and incubated the mixture on a blood-tube rotator at room temperature for 30 min. The whole content was then transferred to a Spin-X column (Corning) and washed 4 times with 0.5 mL of washing solution (butanol:ethanol: water ϭ 5:1:1, vol/vol/vol). Finally the N-glycans were eluted with 200 L of 100 mL/L ethanol, followed by centrifugal vacuum drying. The N-glycans were redissolved with 5 L of 100 mL/L ethanol as the purified N-glycan preparation and stored at Ϫ30°C before MS analysis.
maldi-tof ms-based n-glycome profiling assay N-glycan samples and matrix chemical were added on an 8-spot gold ProteinChip array (Ciphergen Biosystems) by undertaking a sandwich spotting approach. Super-2,5-dihydroxybenzoic acid (DHB) in the presence of NaCl was used as the matrix chemical. A stock solution of super-DHB (1.35 g/L DHB, 0.15 g/L 2-hydroxy-5-methoxybenzoic acid, 10 mmol/L NaCl in 100 mL/L ethanol) was prepared, stored at Ϫ30°C, and 6.7-fold diluted with MilliQ water on the day of MS analysis. First, 0.5 L of super-DHB was spotted and vacuum-dried. Then 0.5 L of the purified N-glycan preparation was spotted and vacuum-dried, followed by sequential addition and vacuum drying of 0.5 L of 500 mL/L acetonitrile and 0.5 L of super-DHB. Finally, 0.5 L of 500 mL/L ethanol was spotted over the spotting area and vacuum-dried to achieve a homogeneous layer of analyte-matrix cocrystals.
The gold ProteinChip arrays were read over the 900 -4000 m/z interval on the ProteinChip PBS II reader of a ProteinChip Biomarker System. The ProteinChip reader was equipped with a nitrogen laser operating at 337 nm wavelength and at 5 microJoule pulse. The mass spectra were acquired at a positive ion mode and an optimized interval of 1200 -3000 m/z. Mass spectrum of each glycan sample was a mean of 610 mass spectra obtained over the sample spot at 61 acquisition positions. The mass spectrum of each sample was smoothed, baseline-subtracted, externally calibrated with the standard N-glycans (see Table 1 in the online Data Supplement), and finally internally calibrated with peaks at 1626.5, 2269.0, and 2947.6 m/z. The glycan peaks with signal-to-noise ratio Ͻ3 among the mass spectra were identified and quantified by use of Biomarker Wizard software (Ciphergen Biosystems). The peak intensities were normalized with the total ion current and subsequently with the total peak intensity. On the mass spectra, each nonsialylated glycan appeared as a single peak with an m/z value equivalent to the mean molecular mass plus 1.0 mass unit (mass of a proton). For the sialylated glycans, sodium salts were formed and detected as a group of consecutive peaks with a step-wise increment of 22 m/z (see Fig. 2 in the online Data Supplement). For a sialylated glycan with n sialic acid residues, n ϩ 1 consecutive peaks were detected. The normalized peak intensities of all consecutive peaks were summed to obtain the normalized peak intensity for the sodium-free parent glycan. Each sample was analyzed in duplicate. Mean values of the duplicates were used in subsequent data mining.
evaluation of quantitative performance of the maldi-tof ms-based n-glycome profiling assay Four standard N-glycans (CalBiochem) were used during evaluation. Structural information of the standard Nglycans is listed in Table 1 in the online Data Supplement. When the reproducibility of the normalized peak intensities was examined, 3 (M3N2, MAN8 and A2) of the standard N-glycans was fixed at 10 pmol. Intraassay CV was determined from 32 identical sample-matrix spots in one single day by use of the same preparations of matrix chemical and reagents. For the interassay CV, the standard glycan mixture was measured in duplicate for 12 consecutive days by using different batches of matrix chemical and reagents, which were prepared freshly on the day of experiment. Linearity relationships between the quantity and normalized peak intensity of each of 4 standard N-glycans were evaluated by varying amounts from 5 to 20 pmol while fixing the amount of the other 3 N-glycans at 10 pmol.
identification of potential diagnostic glycans for liver fibrosis/cirrhosis As in our previous study (18 ) , we used 2 criteria to identify the glycans associated only with disease, (a) the normalized peak intensities must be significantly higher/ lower in patients with typical fibrosis/cirrhosis than in individuals with minimal fibrosis, and (b) the normalized peak intensities must correlate with the degree of fibrosis. The significance analysis of microarray algorithm (Stanford University) (17, 18, 21 ) was used to identify the glycans that were significantly higher/lower in patients with fibrosis/cirrhosis by comparing the glycomic profiles of the cases with minimal fibrosis (Ishak score ϭ 1) with those for cases with typical fibrosis/cirrhosis (Ishak score Ͼ3) at a median false discovery rate of 2.5%. In the significance analysis of microarray analysis, "2-classed, unpaired data" were selected as the data type, and 5000 permutations were performed. Correlations between the degree of fibrosis (Ishak scores) and the peak intensities of the significant glycans were analyzed by the Spearman rank order correlation test.
construction of glycan-based diagnostic model
Log2 values of the age, potential diagnostic glycans, and serological markers [total protein, albumin concentration, international normalized ratio, activated partial thromboplastin time (APTT), alanine transaminase, total bilirubin, ALP, AFP, hemoglobin, leukocyte count, and platelet count] were included as independent variables, and Ishak score was set as the dependent output variable. Forward stepwise linear regression analysis was performed using SPSS (SPSS Inc.) to select the variables with independent prediction values for constructing a diagnostic model to calculate the Fibro-Glyco index. Leave-one-out cross-validation was performed to evaluate the performance of the diagnostic model in detecting significant liver fibrosis (Ishak score Ն3) and cirrhosis (Ishak score Ն5), as we previously described (18 ) .
statistical analyses
The Spearman rank order correlation test was used to examine correlation relationships between the N-glycan peak intensities and the clinical/biochemical variables. The sensitivity and specificity were calculated according to the standard formulas. ROC curves were constructed for differentiating patients with or without significant liver fibrosis (Ishak score Ն3) and for differentiating patients with or without liver cirrhosis (Ishak score Ն5). The likelihood ratios (LRs) were calculated by use of the standard formulas: positive LR (LRϩ) ϭ sensitivity/ (100% Ϫ specificity); negative LR (LRϪ) ϭ (100% Ϫ sensitivity)/specificity.
Results quantitative performance of the maldi-tof ms-based n-glycome profiling assay A representative mass spectrum of 4 standard N-glycans all at 10 pmol is shown in supplementary Fig. 3 . For all 3 standard N-glycans, the intraassay CVs of the normalized peak intensities were Ͻ8% and the interassay CVs were (Table 1) . Linearity study showed that the normalized peak intensity was directly proportional to the relative quantity of a glycan, with an R 2 value Ϫ0.95 for all 4 standard glycans (see Fig. 4 in the online Data Supplement).
serum n-glycome profile and liver fibrosisassociated fingerprint
The representative serum N-glycome mass spectra of serum samples from a healthy individual, a patient with minimal liver fibrosis, and a patient with significant fibrosis are shown in Fig. 1, A-C. Fig. 1D shows that when heat-inactivated PNGase F was used to release the Nglycans, no significant peaks were detected. This finding indicates that the majority of the peaks in the mass spectra were contributed by the N-glycans released from the whole serum proteins. We observed that 5 freeze-thaw cycles did not significantly affect the serum N-glycome profiles (see Fig. 5 in the online Data Supplement).
We found that 55 glycans were matched among the serum samples. At a median false-discovery rate of 2.5%, we identified 15 N-glycans that were significantly higher and 8 N-glycans that were significantly lower in the patient group of typical fibrosis/cirrhosis. Among these 23 significant N-glycans, 13 were positively correlated with the degree of fibrosis, and 8 were negatively correlated (all P values Ͻ0.05; Fig. 2) . Therefore, only 21 glycans were significantly associated with liver fibrosis. ROC curve analyses showed that 17 of these liver fibrosisassociated glycans had potential value in the detection of either liver fibrosis and/or liver cirrhosis (all P values Ͻ0.05). The 1829.7 m/z glycan [area under the curve (AUC) ϭ 0.90] was the best marker for detecting significant liver fibrosis, and the 1444.7 m/z glycan (AUC ϭ 0.83) was the best marker for detecting liver cirrhosis. The results for the 17 potential diagnostic glycans are listed in Table 2 .
correlations between the n-glycan peak intensities and serological markers Among the 17 potential diagnostic glycans, 5 were correlated with albumin concentration (r ϭ 0.417 to 0.490 and Ϫ0.292 to Ϫ0.348; all P values Ͻ0.05); 5 were correlated with total protein (r ϭ 0.329 to 0.351 and Ϫ0.292 to Ϫ0.343; all P values Ͻ0.05); 1 was positively correlated with APTT (r ϭ 0.326; P ϭ 0.027), and 3 were negatively correlated (r ϭ Ϫ0.322 to Ϫ0.356; all P values Ͻ0.05); 4 were correlated with international normalized ratio (r ϭ 0.304 to 0.403 and Ϫ0.380 to Ϫ0.450; all P values Ͻ0.05), resulting in 10 glycans significantly correlated with liver function. Concerning liver inflammation, only the 2606.9 m/z glycan was negatively correlated with alanine transaminase concentration (r ϭ Ϫ0.366; P ϭ 0.012). Concerning liver damage, 1 glycan was positively correlated with total bilirubin (r ϭ 0.319; P ϭ 0.031), whereas 1 glycan was negatively correlated (r ϭ Ϫ0.316; P ϭ 0.032). None of the glycans were correlated with ALP. Three glycans were positively correlated with AFP (r ϭ 0.327 to 0.431; all P values Ͻ0.05). As a result, 76% (13 of 17) of the liver-fibrosis-associated glycans potentially reflected the physiological state of the liver. Finally, it is well known that platelet count is negatively correlated with degrees of fibrosis. We found that 8 glycans were correlated with the platelet count (all P values Ͻ0.05). Therefore, 82% (14 of 17) of the glycans forming the liver fibrosis fingerprint were significantly correlated with the serologic markers that directly reflect the liver physiology and/or with those that are well known to be altered in patients with liver fibrosis (Table 2 ).
linear regression model for detecting liver fibrosis and cirrhosis
Among all the dependent variables (potential diagnostic glycans, serological markers, and age), only N-glycans of 1341.5, 1829.7, 1933.3, 2130.3 m/z (all P Ͻ0.005) were selected as biomarkers with independent diagnostic values and included in the linear regression model for calculating the Fibro-Glyco index. Leave-one-out crossvalidation showed that the Fibro-Glyco index significantly correlated with degrees of liver fibrosis (r ϭ 0.784; P ϭ 0.01). Furthermore, the index was useful in the detection of liver fibrosis and cirrhosis. The ROC curve areas for the Fibro-Glyco index in detection of liver fibrosis and in detection of liver cirrhosis both were 0.91 (Fig. 3) . At 84% specificity, the sensitivity for detecting liver fibrosis was 85%, the overall accuracy was 85%, and the LRϩ and LRϪ were 5.4 and 0.18, respectively. At 83% specificity, the sensitivity for detecting liver cirrhosis was 88%, the overall accuracy was 85%, and the LRϩ and LRϪ were 5.1 and 0.14, respectively.
Discussion
Although MALDI-TOF MS has been widely used to characterize the structure of glycans, this is first study indicating that MALDI-TOF MS is also applicable to quantitative profiling of a complex mixture of glycans. To achieve this quantitative capability, we made 2 important measurements, one to ensure a homogeneous layer of glycan-matrix cocrystals and the other to scan the glycanmatrix spot to obtain 610 mass spectra, the mean of which was used as the final mass spectrum for each glycan sample. Previously, we showed that both measures were important to obtain a quantitative mass spectrum for profiling a mixture of protein/peptide molecules (22 ) .
In the present study, using the serum N-glycome profiling assay, we successfully identified a panel of Clinical Chemistry 53, No. 7, 2007 serum N-glycans as potential markers for detecting liver fibrosis and liver cirrhosis; 82% (14 of 17) of the glycans with potential diagnostic values were significantly correlated with the serological markers that directly reflect liver physiology and/or with those that are well known to be altered in patients with liver fibrosis. These findings also serve as indirect evidence indicating that identified diagnostic glycans have clinical meanings associated with the disease being studied. Callewaert et al. (11 ) applied the DNA sequencer to profile sialidase-treated N-glycans from the whole serum proteins in patients with and without liver cirrhosis. The present study strongly suggested that the serum N-glycome profile is useful in predicting not only liver cirrhosis but also liver fibrosis. As far as we know, this is the first study demonstrating such clinical importance in humans. Because only 46 patients were examined in this study, we are undertaking a similar study with a much larger sample size to confirm the clinical value of the present diagnostic model. Further studies are also needed to determine whether the same serum N-glycan-based model can be used to detect liver fibrosis/cirrhosis with other underlying causes, such as chronic hepatitis C infection and chronic alcohol abuse.
N-glycans are different from peptides or proteins in terms of sequence-structure analysis. Because human Nlinked glycans all contain the same chitobiose core [2 N-acetyl-glucosamines (GlcNAcs) attached to a trimannose] and are synthesized by a well-defined pathway, an accurate mass measurement will generally permit prediction of structure (23, 24 ) . We attempted to predict the structures of the 4 major diagnostic glycans (1341.5, 1829.7, 1933.3, and 2130.3 m/z) from their mean m/z values by searching the Consortium for Functional Glycomics database and using Expasy GlycoMod (23 ) with an acceptable error tolerance Յ0.05%. The predicted structures of the 4 glycans were successfully matched to those that had been observed in human (Fig. 4) .
With the predicted structures, we found that 3 diagnostic N-glycans (1341.5, 1829.7, and 2130.3 m/z) showing positive correlations with fibrosis stages contain a proximal fucose and/or a bisecting GlcNAc. Because liver . LIϪ, peak intensity negatively correlated with liver inflammation (negatively correlated with ALT-alanine transaminase concentration). LDϩ, peak intensity positively correlated with liver damage (positively correlated with total bilirubin concentration). LDϪ, peak intensity negatively correlated with liver damage (negatively correlated with total bilirubin concentration). AFPϩ, peak intensity positively correlated with AFP concentration. PLCϩ, peak intensity positively correlated with platelet count. PLCϪ, peak intensity negatively correlated with platelet count. WBCϩ, peak intensity positively correlated with white blood cell count. WBCϪ, peak intensity negatively correlated with white blood cell count. (28 ) . Our serum N-glycome profiling assay has several advantages. The assay can easily be performed by laboratories already equipped with the SELDI ProteinChip system, and only 2 L of serum is needed for profiling the serum N-glycome. The assay is high-throughput, so a maximum of 96 serum samples can be examined in duplicate within 2 working days. As with the serum proteomic profiling assay, it is not necessary to know the structure of a diagnostic glycan, because a diagnostic N-glycan can be reproducibly recognized and quantified through its unique m/z value. When a MALDI TOF/TOF MS or MALDI Q-TOF MS instrument is used instead of the MALDI TOF MS instrument, the structures of the glycans can be further obtained by tandem MS analysis.
In addition to liver fibrosis, our assay has the potential to be applied to the diagnoses of other diseases, such as CDG. Multiple serum glycoproteins with abnormal glycosylation have been observed in patients with CDG (29, 30 ) . Furthermore, our assay can be modified for other applications, such as quantitative profiling of glycans on a single protein. For example, quantitative profiling of the N-glycans detached from transferrin should be useful in detecting alcohol abuse. Quantitative analysis of specific N-glycans on haptoglobin may be useful in the diagnosis of liver cancer (31 ).
In conclusion, we have developed a high-throughput assay for quantitative profiling of serum N-glycome using a system originally designed for serum proteomic profiling. Using diagnosis of liver fibrosis as an example, we have demonstrated the potential of applying our assay to biomarker discovery. 
